Swiss National Bank
APGE

Swiss National Bank’s Apogee Therapeutics APGE Stock Holding History

Swiss National Bank’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Buy
76,700
+1,100
+1% +$99.1K 0.01% 1007
2026
Q1 		$6.36M Buy
75,600
+12,700
+20% +$922K ﹤0.01% 1214
2025
Q4 		$4.75M Buy
62,900
+19,500
+45% +$1.23M ﹤0.01% 1382
2025
Q3 		$1.72M Buy
43,400
+800
+2% +$30.5K ﹤0.01% 1925
2025
Q2 		$1.85M Sell
42,600
-1,000
-2% -$38K ﹤0.01% 1845
2025
Q1 		$1.63M Sell
43,600
-700
-2% -$27.1K ﹤0.01% 1884
2024
Q4 		$2.01M Buy
44,300
+6,600
+18% +$337K ﹤0.01% 1851
2024
Q3 		$2.21M Sell
37,700
-4,500
-11% -$216K ﹤0.01% 1806
2024
Q2 		$1.66M Buy
42,200
+900
+2% +$43.7K ﹤0.01% 1911
2024
Q1 		$2.74M Buy
41,300
+8,300
+25% +$362K ﹤0.01% 1661
2023
Q4 		$922K Buy
+33,000
New +$662K ﹤0.01% 2283

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Swiss National Bank's APGE Position: Q2 2026 in Review

Swiss National Bank increased its Apogee Therapeutics (APGE) stake by 1.5% in Q2 2026, buying an estimated $99.1K and bringing the position to 76,700 shares worth $10.2M. The position accounts for 0.01% of the portfolio, ranked #1007.

Swiss National Bank first reported a position in APGE in Q4 2023 and has held it in 11 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Swiss National Bank held 76,700 shares of Apogee Therapeutics worth $10.2M as of Q2 2026.
  • Swiss National Bank bought 1,100 Apogee Therapeutics shares in Q2 2026, an estimated $99.1K.
  • Apogee Therapeutics made up 0.01% of Swiss National Bank's portfolio in Q2 2026, its #1007 holding.
  • Swiss National Bank first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.